JP2008133192A - Antidiabetic agent - Google Patents
Antidiabetic agent Download PDFInfo
- Publication number
- JP2008133192A JP2008133192A JP2005285553A JP2005285553A JP2008133192A JP 2008133192 A JP2008133192 A JP 2008133192A JP 2005285553 A JP2005285553 A JP 2005285553A JP 2005285553 A JP2005285553 A JP 2005285553A JP 2008133192 A JP2008133192 A JP 2008133192A
- Authority
- JP
- Japan
- Prior art keywords
- isocartamidine
- antidiabetic agent
- cartamidine
- flavanone
- flavanone compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 8
- 229940125708 antidiabetic agent Drugs 0.000 title claims abstract description 7
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003949 flavanone Natural products 0.000 claims abstract description 13
- -1 flavanone compound Chemical class 0.000 claims abstract description 13
- 235000011981 flavanones Nutrition 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 3
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 3
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 8
- 239000008103 glucose Substances 0.000 abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- NPLTVGMLNDMOQE-NSHDSACASA-N carthamidin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-NSHDSACASA-N 0.000 abstract description 5
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- NUNODKNZSZKXGY-UHFFFAOYSA-N isocarthamidin Natural products C1=CC(O)=CC=C1C1OC2=C(O)C(O)=CC(O)=C2C(=O)C1 NUNODKNZSZKXGY-UHFFFAOYSA-N 0.000 abstract description 4
- 235000012054 meals Nutrition 0.000 abstract description 3
- NUNODKNZSZKXGY-LBPRGKRZSA-N (2s)-5,7,8-trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=C(O)C(O)=CC(O)=C2C(=O)C1 NUNODKNZSZKXGY-LBPRGKRZSA-N 0.000 abstract description 2
- JVXZRQGOGOXCEC-UHFFFAOYSA-N scutellarein Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C(O)=C(O)C=C2O1 JVXZRQGOGOXCEC-UHFFFAOYSA-N 0.000 abstract description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical group C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- FTVWIRXFELQLPI-CYBMUJFWSA-N (+)-Naringenin Natural products C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
本発明は、抗糖尿病活性を有するフラバノン化合物であるカルタミジンおよびイソカルタミジンに関する。 The present invention relates to cartamidine and isocartamidine which are flavanone compounds having anti-diabetic activity.
近年、摂取カロリーの過多が生活習慣病の原因となっていることから、摂取カロリーの制限が求められている。代表的な生活習慣病のうち、特に糖尿病は我が国において最も患者数が多い生活習慣病の一つである。糖尿病の特徴は、食事により摂取された炭水化物由来の糖分が消化管から吸収されて血中に入ったときに、血糖値が高過ぎたり、高血糖状態が持続したりすることであり、これら炭水化物の消化を抑え、生体内でエネルギーに変換されるのを阻止することは糖尿病など生活習慣病の予防・治療に有効であると考えられる。 In recent years, excessive intake of calories has been a cause of lifestyle-related diseases, and therefore, restriction of intake calories has been demanded. Among typical lifestyle-related diseases, diabetes is one of the most common lifestyle-related diseases in Japan. A characteristic of diabetes is that when sugars derived from carbohydrates taken from meals are absorbed from the digestive tract and enter the blood, the blood sugar level is too high or the hyperglycemic state persists. It is considered effective to prevent the digestion of food and prevent it from being converted into energy in vivo for the prevention and treatment of lifestyle-related diseases such as diabetes.
ここで、本発明に関連のある事項として、フラバノン化合物であるカルタミジンおよびイソカルタミジンについて、以下説明する。 Here, as a matter relevant to the present invention, cartamidine and isocartamidine which are flavanone compounds will be described below.
カルタミジン(carthamidin)は、化学式Ｃ15Ｈ12Ｏ6のフラバノン化合物（4',5,6,7-tetrahydroxyflavanone）であり、ナリンゲニン（naringenin；4',5,7-trihydroxyflavanone）の６位に水酸基を有する化合物、いわゆる６−ヒドロキシナリンゲニン（6-hydroxynaringenin）のことである。
イソカルタミジン(isocarthamidin)は、化学式Ｃ15Ｈ12Ｏ6のフラバノン化合物（4',5,7,8-tetrahydroxyflavanone）であり、いわゆる８−ヒドロキシナリンゲニン（8-hydroxynaringenin）のことである。
Carthamidin is a flavanone compound (4 ', 5,6,7-tetrahydroxyflavanone) with the chemical formula C 15 H 12 O 6 , and a hydroxyl group is placed at the 6-position of naringenin (naringenin; 4', 5,7-trihydroxyflavanone). It is a so-called 6-hydroxynaringenin.
Isocarthamidin is a flavanone compound (4 ′, 5,7,8-tetrahydroxyflavanone) having the chemical formula C 15 H 12 O 6 and is a so-called 8-hydroxynaringenin.
カルタミジン及びイソカルタミジンに関して、例えば、以下の文献がある。
特許文献１には、イソカルタミジンの消臭効果が、特許文献２〜４にはこれらの化合物の抗酸化効果が、特許文献５にはこれらの化合物のコガネバナからの抽出例が、それぞれ開示されている。
また、非特許文献では、紅花の紅色色素などを酸加水分解することで生成することが知られており、例えば、非特許文献１、非特許文献２などではそれらの合成法が報告されている。また、非特許文献３には、コガネバナの葉抽出物から分離精製された例が報告されている。その他、非特許文献４、非特許文献５などには、抗酸化効果が示されている。
Patent Document 1 discloses the deodorizing effect of isocartamidine, Patent Documents 2 to 4 disclose the antioxidant effect of these compounds, and Patent Document 5 discloses an extraction example of these compounds from Cognevana. ing.
In addition, in non-patent literature, it is known that the red pigment of safflower is generated by acid hydrolysis. For example, Non-patent literature 1, Non-patent literature 2 and the like report their synthesis methods. . Non-Patent Document 3 reports an example of separation and purification from a leaf extract of Scutellaria. In addition, Non-Patent Document 4, Non-Patent Document 5, and the like show an antioxidant effect.
本発明の目的は、新規な抗糖尿病剤を提供することである。 An object of the present invention is to provide a novel antidiabetic agent.
本発明者らは上記事情に鑑み、種々の炭水化物消化酵素を阻害する物質を種々検討した結果、植物中に含まれ、種々の炭水化物消化酵素阻害に優れたフラバノン化合物であるカルタミジンおよびイソカルタミジンを見出した。 In view of the above circumstances, the present inventors have studied various substances that inhibit various carbohydrate digestive enzymes. As a result, the present inventors have found that cartamidine and isocartamidine, which are flavanone compounds contained in plants and excellent in inhibiting various carbohydrate digestive enzymes. I found it.
従来、これらのフラバノン化合物は、消臭効果、抗酸化効果を発揮するに止まっており、食後血糖値上昇抑制作用に関しては、現在まで知られていなかった。それに対し、本発明では、これらのフラバノン化合物が食後の過血糖状態を抑制して糖尿病の予防及び治療に優れた効果を有することを新規に見出した。 Conventionally, these flavanone compounds have only been able to exert a deodorizing effect and an antioxidant effect, and the postprandial blood glucose level inhibitory action has not been known so far. On the other hand, in the present invention, it has been newly found that these flavanone compounds have an excellent effect in the prevention and treatment of diabetes by suppressing the hyperglycemic state after meal.
そこで、本発明では、フラバノン化合物であり、「化１」の構造を有するカルタミジン（１）、及び／又は、同じくフラバノン化合物であり「化２」の構造を有するイソカルタミジン（２）を有効成分として含有する抗糖尿病剤を提供する。 Therefore, in the present invention, cartamidine (1) which is a flavanone compound and has a structure of “Chemical Formula 1” and / or isocartamidine (2) which is also a flavanone compound and has a structure of “Chemical Formula 2” is an active ingredient As an antidiabetic agent.
なお、カルタミジン及びイソカルタミジンの好適な適用量は、年齢、症状等によって異なるが、例えば、成人１回につき１〜５００ｍｇ程度、好ましくは５〜３００ｍｇ程度、である。 In addition, although the suitable application amount of a cartamidine and an isocartamidine changes with age, a symptom, etc., it is about 1-500 mg per adult, Preferably it is about 5-300 mg.
本発明に係る化合物は、糖尿病の予防及び治療に有効である。 The compound according to the present invention is effective for the prevention and treatment of diabetes.
実施例１では、カルタミジン及びイソカルタミジンについて、α−グルコシダーゼ阻害活性の測定を行った。 In Example 1, the α-glucosidase inhibitory activity was measured for cartamidine and isocartamidine.
実験手順の概要は次の通りである。
ラットアセトン粉末（ＳＩＧＭＡ社製）に９倍量の０．０５Ｍマレイン酸緩衝液（ｐＨ６．０）を加え、超音波処理後、３０００ｒｐｍ・１０分間遠心、上清を酵素液とした。マレイン酸緩衝液（ｐＨ６．０）に所定の濃度で溶解させたカルタミジン又はイソカルタミジン５０μＬに、マレイン酸緩衝液（ｐＨ６．０）に溶解した２％ショ糖５０μＬを加え、３７℃・５分間プレインキュベート後、マレイン酸緩衝液（ｐＨ６．０）で２倍希釈した酵素液を５０μＬ加え、３７℃・６０分間反応した。反応終了後、９５℃・１０分間で酵素を失活させ、１５０００ｒｐｍ・１０分間遠心後、上清中のグルコース量をＳＹＮＣＨＲＯＮ ＣＸ３Δ（ＢＥＣＫＭＡＮ社製）にて測定した。
また、コントロールとして前記試料溶液の代わりにマレイン酸緩衝液（ｐＨ６．０）のみの溶液を使用して同様に測定した。
The outline of the experimental procedure is as follows.
Nine times the amount of 0.05 M maleate buffer (pH 6.0) was added to rat acetone powder (manufactured by SIGMA), sonicated, centrifuged at 3000 rpm for 10 minutes, and the supernatant was used as the enzyme solution. 50 μL of 2% sucrose dissolved in maleate buffer (pH 6.0) is added to 50 μL of cartamidine or isocartamidine dissolved in maleate buffer (pH 6.0) at a predetermined concentration, and the temperature is 37 ° C. for 5 minutes. After pre-incubation, 50 μL of enzyme solution diluted 2-fold with maleic acid buffer solution (pH 6.0) was added, and reacted at 37 ° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated at 95 ° C. for 10 minutes, centrifuged at 15000 rpm for 10 minutes, and the amount of glucose in the supernatant was measured with SYNCHRON CX3Δ (manufactured by BECKMAN).
Moreover, it measured similarly using the solution of only maleic acid buffer (pH 6.0) instead of the said sample solution as control.
結果を表１に示す。
表中の数値（下段）は、酵素阻害活性を示す値（％）であり、各サンプルを用いた場合におけるグルコース量を、マレイン酸緩衝液を用いた場合（コントロール）におけるグルコース量で除することにより算出した。
The numerical values in the table (lower) are values (%) indicating enzyme inhibitory activity, and the amount of glucose when using each sample is divided by the amount of glucose when using maleate buffer (control). Calculated by
その結果、表１に示す通り、カルタミジン及びイソカルタミジンは、それぞれ、優れたα−グルコシダーゼ阻害活性を有することがわかった。 As a result, as shown in Table 1, it was found that cartamidine and isocartamidine each have excellent α-glucosidase inhibitory activity.
実施例２では、カルタミジン及びイソカルタミジンについて、マルターゼ阻害活性の測定を行った。 In Example 2, maltase inhibitory activity was measured for cartamidine and isocartamidine.
実験手順の概要は次の通りである。
ラットアセトン粉末（ＳＩＧＭＡ社製）に９倍量の０．０５Ｍマレイン酸緩衝液（ｐＨ６．０）を加え、超音波処理後、３０００ｒｐｍ・１０分間遠心、上清を酵素液とした。マレイン酸緩衝液（ｐＨ６．０）に所定の濃度で溶解させたカルタミジン又はイソカルタミジン５０μＬに、マレイン酸緩衝液（ｐＨ６．０）に溶解した２％マルトース５０μＬを加え、３７℃・５分間プレインキュベート後、０．０５Ｍマレイン酸緩衝液（ｐＨ６．０）で２０倍希釈した酵素液を５０μＬ加え、３７℃・６０分間反応した。反応終了後、９５℃・１０分間で酵素を失活させ、１５０００ｒｐｍ・１０分間遠心後、上清中のグルコース量をＳＹＮＣＨＲＯＮ ＣＸ３Δ（ＢＥＣＫＭＡＮ社製）にて測定した。
また、コントロールとして前記試料溶液の代わりにマレイン酸緩衝液（ｐＨ６．０）のみの溶液を使用して同様に測定した。
The outline of the experimental procedure is as follows.
Nine times the amount of 0.05 M maleate buffer (pH 6.0) was added to rat acetone powder (manufactured by SIGMA), sonicated, centrifuged at 3000 rpm for 10 minutes, and the supernatant was used as the enzyme solution. 50 μL of 2% maltose dissolved in maleate buffer solution (pH 6.0) is added to 50 μL of cartamidine or isocartamidine dissolved in maleate buffer solution (pH 6.0) at a predetermined concentration. After the incubation, 50 μL of an enzyme solution diluted 20-fold with 0.05 M maleate buffer (pH 6.0) was added and reacted at 37 ° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated at 95 ° C. for 10 minutes, centrifuged at 15000 rpm for 10 minutes, and the amount of glucose in the supernatant was measured with SYNCHRON CX3Δ (manufactured by BECKMAN).
Moreover, it measured similarly using the solution of only maleic acid buffer (pH 6.0) instead of the said sample solution as control.
結果を表２に示す。
表中の数値（下段）は、前記と同様、酵素阻害活性を示す値（％）であり、各サンプルを用いた場合におけるグルコース量を、マレイン酸緩衝液を用いた場合（コントロール）におけるグルコース量で除することにより算出した。
The numerical value (lower part) in the table is a value (%) indicating enzyme inhibitory activity as described above, and the amount of glucose when using each sample is the amount of glucose when using maleate buffer (control). It was calculated by dividing by.
その結果、表２に示す通り、カルタミジン及びイソカルタミジンは、それぞれ、優れたマルターゼ阻害活性を有することがわかった。
As a result, as shown in Table 2, it was found that cartamidine and isocartamidine each have excellent maltase inhibitory activity.
Claims (3)
Anti-diabetic containing flavanone compound and cartamidine (1) having the structure of the following "chemical formula 1" and / or isocartamidine (2) having the structure of the following "chemical formula 2" and the same flavanone compound as an active ingredient Agent.
The antidiabetic agent according to claim 1 or 2, which has a maltase inhibitory activity or a suppressive activity.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005285553A JP2008133192A (en) | 2005-09-29 | 2005-09-29 | Antidiabetic agent |
| PCT/JP2006/319561 WO2007037423A1 (en) | 2005-09-29 | 2006-09-29 | Antidiabetic agent |
| JP2007537734A JP4966859B2 (en) | 2005-09-29 | 2006-09-29 | Antidiabetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005285553A JP2008133192A (en) | 2005-09-29 | 2005-09-29 | Antidiabetic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008133192A true JP2008133192A (en) | 2008-06-12 |
Family
ID=37899843
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005285553A Pending JP2008133192A (en) | 2005-09-29 | 2005-09-29 | Antidiabetic agent |
| JP2007537734A Expired - Fee Related JP4966859B2 (en) | 2005-09-29 | 2006-09-29 | Antidiabetic |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537734A Expired - Fee Related JP4966859B2 (en) | 2005-09-29 | 2006-09-29 | Antidiabetic |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP2008133192A (en) |
| WO (1) | WO2007037423A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010248130A (en) * | 2009-04-16 | 2010-11-04 | Kureha Corp | Anti-diabetic agent and use thereof |
| JP2016522255A (en) * | 2013-06-19 | 2016-07-28 | アクセス ビジネス グループ インターナショナル エルエルシーＡｃｃｅｓｓ Ｂｕｓｉｎｅｓｓ Ｇｒｏｕｐ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｌｃ | Plant-based ketohexokinase inhibitors to support weight management |
| JP2019205386A (en) * | 2018-05-29 | 2019-12-05 | 丸善製薬株式会社 | INHIBITOR OF α-GLUCOSIDASE ACTIVITY AND SUPPRESSOR OF RISE IN BLOOD SUGAR LEVEL |
| JP2021187791A (en) * | 2020-06-01 | 2021-12-13 | 江崎グリコ株式会社 | Diacylglycerol kinase α activator |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5759813A (en) * | 1980-09-29 | 1982-04-10 | Takeda Chem Ind Ltd | Alpha-glucosidase inhibitor |
| JPH0238580B2 (en) * | 1981-06-02 | 1990-08-31 | Takeda Chemical Industries Ltd | BARIOORUAMINNONNCHIKANJUDOTAI * SONOSEIZOHOOYOBYOTO |
| JPH03240725A (en) * | 1990-02-15 | 1991-10-28 | Senjiyu Seiyaku Kk | Maillard reaction inhibitor |
| KR20000019716A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising bioflavonoid compounds for descending blood sugar |
| JP2000102383A (en) * | 1998-09-30 | 2000-04-11 | Nisshin Sugar Mfg Co Ltd | Alfa-glucosidase inhibitor containing extract of perilla frutescens crispa as active ingredient, sugar composition, and food and drink, containing the inhibitor |
| JP2000229874A (en) * | 1999-02-09 | 2000-08-22 | Nippon Synthetic Chem Ind Co Ltd:The | α-glucosidase inhibitor |
| DE60216332T2 (en) * | 2002-12-17 | 2007-07-05 | Council Of Scientific & Industrial Research | ANTIOXYDOMANT FROM NATURAL SOURCE |
| RU2228673C1 (en) * | 2003-06-20 | 2004-05-20 | Московский государственный университет прикладной биотехнологии | Antioxidant-containing food product from baikal scull-cap extract |
-
2005
- 2005-09-29 JP JP2005285553A patent/JP2008133192A/en active Pending
-
2006
- 2006-09-29 JP JP2007537734A patent/JP4966859B2/en not_active Expired - Fee Related
- 2006-09-29 WO PCT/JP2006/319561 patent/WO2007037423A1/en not_active Ceased
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010248130A (en) * | 2009-04-16 | 2010-11-04 | Kureha Corp | Anti-diabetic agent and use thereof |
| JP2016522255A (en) * | 2013-06-19 | 2016-07-28 | アクセス ビジネス グループ インターナショナル エルエルシーＡｃｃｅｓｓ Ｂｕｓｉｎｅｓｓ Ｇｒｏｕｐ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｌｃ | Plant-based ketohexokinase inhibitors to support weight management |
| JP2019205386A (en) * | 2018-05-29 | 2019-12-05 | 丸善製薬株式会社 | INHIBITOR OF α-GLUCOSIDASE ACTIVITY AND SUPPRESSOR OF RISE IN BLOOD SUGAR LEVEL |
| JP7239135B2 (en) | 2018-05-29 | 2023-03-14 | 丸善製薬株式会社 | α-Glucosidase activity inhibitor and blood sugar elevation inhibitor |
| JP2021187791A (en) * | 2020-06-01 | 2021-12-13 | 江崎グリコ株式会社 | Diacylglycerol kinase α activator |
| JP7594371B2 (en) | 2020-06-01 | 2024-12-04 | 江崎グリコ株式会社 | Diacylglycerol kinase α activator |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2007037423A1 (en) | 2009-04-16 |
| WO2007037423A1 (en) | 2007-04-05 |
| JP4966859B2 (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ohta et al. | α-Glucosidase inhibitory activity of a 70% methanol extract from Ezoishige (Pelvetia babingtonii de Toni) and its effect on the elevation of blood glucose level in rats | |
| JP7145566B2 (en) | Composition for adjusting intestinal flora | |
| JP4966859B2 (en) | Antidiabetic | |
| JP4516282B2 (en) | Novel substance having α-glucosidase inhibitory activity and food containing the same | |
| JP4556009B2 (en) | Anti-inflammatory agents, preventive or ameliorating agents for allergic diseases and functional foods | |
| JP5307019B2 (en) | Bone resorption inhibitor and beverages, foods and pharmaceuticals containing the same | |
| KR101500836B1 (en) | Complex extract of Quercus variabilis fractions and composition for treating or preventing diabetes comprising the same | |
| JP5255862B2 (en) | Antidiabetic | |
| JP2009060792A (en) | Tablet or capsule food. | |
| Saini et al. | In vitro enzyme inhibitory and free radical scavenging potentials of an Aegle marmelos endophytic actinomycete extract | |
| EP2540315B1 (en) | Use of salacia extract for controlling production of primary bile acid and secondary bile acid for the prophylaxis of colorectal cancer | |
| JP4403457B2 (en) | α-Glucosidase inhibitor | |
| JP2009137920A (en) | Glycogen phosphorylase inhibitor | |
| CN115671254A (en) | A kind of Antarctic krill peptide-polyphenol compound and its application | |
| KR101302043B1 (en) | Chitosan Oligosaccharide comprising of deep sea water for detoxicating alcohol or eliminating alcoholic | |
| KR100953177B1 (en) | Resveratrol derivative having anti-inflammatory and immono-suppressive effects and the pharmaceutical composition containing the same | |
| JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
| JP5710663B2 (en) | Tablet or capsule food. | |
| Nwanjo et al. | Effect of aqueous extract of Gongronema latifolium on some indices of liver function in rats | |
| KR102507494B1 (en) | Composition for preventing, alleviating, or treating muscle weakness diseases comprising celery seed extract as an active ingredient | |
| Adepoju et al. | Biological Activity of Selected Phenolic Compounds of Allium sativum As Neuromodulatory Agent in Drosophila melanogaster: Molecular Docking Study | |
| JP3991026B2 (en) | Preventive and therapeutic agent for gastritis and stomach / duodenal ulcer | |
| JP2008297230A (en) | Cholesterol reducing composition | |
| JP2009292766A (en) | Agent for suppressing increase of blood sugar level and food for suppressing increase of blood sugar level | |
| CN1890205A (en) | Remedy |